



Efficacy of Herbal and Alternative Medicines as Adjunct Therapies for Chronic Kidney Disease Management: A Comprehensive Review

¹-Rahma Turki Hassan Alshamrani,²-Mohammed Ali Mohammed Alsahli,³- Abdulaziz Saleh Alyahya,⁴-Sultan Abdullah Alqahtani,⁵-Abdulrahman Saleh Alanazi,⁶-Bejad Muteb Saad Alotaibi,⁷-Mohammed Ali Mohammed Adawi,⁸-Moath Abdullah Altokis,⁹-Adel Ali Alshehri,¹⁰-Khalid Hamoud Alharbi,¹¹mohammed Fahad Alotaibi,¹²-Ali Ahmed Esawi,¹³-Abdullah Mudshir Mansour Alanazi,¹⁴-Amnah Hadi Hassan Al Marzooq,¹⁵-Fayez Fayadh Helal Alanazi

¹ Ksa, Ministry Of Health, Al-Laith General Hospital

²Ksa, Ministry Of Health, Rawidat Al-Ared General Hospital

³Ksa, Ministry Of Health, Dawadmi General Hospital

⁴Ksa, Ministry Of Health

⁵Ksa, Ministry Of Health, Al Muzahmiyah General Hospital

⁶Ksa, Ministry Of Health, Irada And Mental Health Hospital In Al Kharj

⁷Ksa, Ministry Of Health, Al-Darb General Hospital

⁸Ksa, Ministry Of Health, King Salman Hospital Hospital

⁹Ksa, Ministry Of Health, King Salman Hospital

¹⁰Ksa, Ministry Of Health, King Salman Hospital

¹¹Ksa, Ministry Of Health, King Salman Hospital

¹²Ksa, Ministry Of Health, King Salman Hospital

¹³Ksa, Ministry Of Health, Al-Sahdawi Primary Health Care Center

¹⁴Ksa, Ministry Of Health, Jazan Specialist Hospital

¹⁵Ksa, Ministry Of Health, King Khalid Hospital In Al Kharj

Abstract

Background: Chronic kidney disease (CKD) significantly impacts patient quality of life and is associated with numerous complications, including uremic pruritus and anemia. Traditional treatments often fail to effectively manage these symptoms, leading to increased patient interest in alternative medical systems (AMS) such as Traditional Chinese Medicine (TCM), Ayurveda, and naturopathy.

Methods: This review systematically analyzes the efficacy of AMS in alleviating CKD-related symptoms through a comprehensive literature search in databases such as MEDLINE, Embase, and Scopus, covering studies published until 2023. Randomized controlled trials (RCTs) focusing on CKD patients utilizing herbal and alternative therapies were included.

Results: The review identified significant benefits of AMS, particularly TCM and Ayurveda, in managing CKD symptoms. Notable findings include a 49% reduction in pruritus symptoms with homeopathic treatments and improved hemoglobin levels in patients receiving TCM therapies. Additionally, herbal remedies like Huangkui and silymarin demonstrated effects on proteinuria and renal function enhancement, respectively. The integration of AMS with conventional therapies showed promising synergistic effects.

Conclusion: The findings indicate that herbal and alternative medicines can serve as effective adjunct therapies in managing chronic kidney disease, particularly in symptom relief and improving overall patient outcomes. However, further large-scale RCTs are necessary to validate these results and establish

standardized treatment protocols. Healthcare practitioners should consider individual patient profiles when incorporating AMS into treatment plans.

Keywords: Chronic kidney disease, alternative medicine, herbal therapies, Traditional Chinese Medicine, patient outcomes.

Received: 16 october 2023 **Revised:** 29 November 2023 **Accepted:** 13 December 2023

Introduction

Chronic kidney disease (CKD) is a predominant worldwide mortality factor, impacting 13.4% of the global population [1]. Deterioration of renal function results in problems associated with chronic kidney disease, including uremia, anemia, and electrolyte imbalances [2]. These problems often present as symptoms including pruritus, discomfort, sleeplessness, and muscular cramps. This thus adversely affects patients' quality of life [3,4]. As individuals with chronic kidney disease (CKD) approach end-stage renal disease (ESRD), the frequency and intensity of these symptoms increase.

Notwithstanding medical advancements and the emergence of novel therapeutics in recent decades, appropriate treatments for many symptoms arising from CKD-related consequences remain ambiguous, perhaps owing to their intricate biology [5]. Uremic pruritus occurs in around 20% of pre-dialysis chronic kidney disease patients and 40% of end-stage renal disease patients [6]. Despite the common use of emollients, gabapentin, and antihistamines, the effectiveness data are often sourced from restricted trials, and their utilization is constrained by side effects [7].

The use of alternative medical systems (AMS), a fundamental component of complementary and alternative medicine (CAM), has risen during the last two decades [8]. AMS is characterized as a "comprehensive system of health theory and practice that evolved independently from conventional medicine" [9]. Approximately 18% of dialysis patients have used some kind of AMS [10,11]. Moreover, the administration of AMS treatments, including traditional Chinese medicine (TCM), by qualified practitioners often mitigates the risk of adverse effects, hence enhancing their attractiveness as viable therapeutic options [11].

Previous research has shown that AMS effectively alleviates symptoms like pain, nausea, and exhaustion in non-CKD patient groups. The use of TCM formulations, including Liu Junzi Tang and Xiao Banxia Plus Fuling, has shown effectiveness in alleviating cancer-related pain and chemotherapy-induced nausea and vomiting [12]. Furthermore, Chinese medicines including Curcuma longa and Panax ginseng have shown effectiveness in inducing apoptosis in cancer cells and suppressing tumor spread in patients with malignancies [13]. Further research demonstrated that a multi-modal Ayurvedic therapy method effectively alleviated symptoms of knee osteoarthritis, including pain and stiffness while enhancing functionality [14]. The growing body of research endorsing AMS has resulted in a surge of healthcare facilities implementing and offering these integrated services, which are backed by insurance coverage [15].

Numerous studies have been undertaken to evaluate the effectiveness of AMS in addressing CKD-related diseases and symptoms, including uremic pruritus and anemia, among patients with chronic kidney disease (CKD). Research evaluating the effectiveness of homeopathic verum in CKD patients demonstrated a 49% decrease in pruritus symptoms after 30 days of therapy [16]. Separate research assessing TCM in patients with glomerulonephritis demonstrated an enhancement in hemoglobin levels after 24 weeks of treatment [16,17].

Current reviews evaluating the role of AMS are restricted to particular indications, including uremic pruritus [18], the application of AMS subtypes in distinct CKD subgroups, such as the utilization of Chinese herbal medicine in diabetic kidney disease, and specific AMS treatments, such as the administration of *Astragalus* [19-21]. This research sought to outline and assess the extensive functions and effectiveness of AMS as viable alternative therapy alternatives for patients with CKD. The review's findings will assist clinicians in comprehending the effectiveness of AMS for CKD patients, therefore permitting informed talks with patients using or contemplating these medications.

Methods

A literature review was performed using MEDLINE, Embase, Scopus, CENTRAL, CINAHL, and PsycINFO. No restrictions were imposed on the commencement date, and investigations conducted until 2023 were included. Searches included essential terminology pertinent to chronic kidney disease (CKD), randomized controlled trials (RCT), and antimicrobial stewardship (AMS).

The Therapeutic Applications of AMS for CKD Patients

Among the four classes of AMS, TCM has been the most extensively researched class, demonstrating effectiveness in ameliorating CKD-related symptoms and outcomes [3,7,22-38]. Among the assessed TCM therapies, Huangkui, TWHF, and acupuncture have shown effectiveness in diminishing proteinuria and alleviating symptoms of uremic pruritus. The treatment foundation of Traditional Chinese Medicine for chronic kidney disease is based on the restoration of vital energy and blood feeding, the elimination of heat and reduction of moisture, and the control of Yin and Yang inside the body. In Western medicine, this is seen as a decrease in inflammation and oxidative stress, together with an improvement in microcirculation and metabolic enhancement [38]. Huangkui, or *Abelmoschus manihot*, diminishes proteinuria by eliminating oxygen radicals, enhancing circulation and the elimination of immunological complexes, and mitigating inflammation and renal tubular epithelial damage [39]. Triptolide, the principal component of TWHF, inhibits the nuclear factor kappa b (NF- κ B) signaling pathway and obstructs the activation of T lymphocytes and certain inflammatory cytokines (TNF- α , IL-1 β , IL-6, and IFN- γ), alongside its protective effects on podocytes [40,41]. Two of the studies indicated that the combination of Traditional Chinese medication (TCM) and Western medication, namely the administration of Huangkui capsules and losartan tablets to reduce proteinuria, is more effective than either TCM or Western medicine used alone. This contributes to the current data about the possible uses of Traditional Chinese Medicine in conjunction with mainstream medical care. Patients on TWHF should undergo frequent assessments of potassium levels and liver enzymes owing to the potential risk of hyperkalemia and elevated liver enzymes.

Acupuncture induces the release of endogenous opiate-like chemicals, which are believed to mitigate both peripheral and central itch perception [42]. Far infrared (FIR) therapies that stimulate acupoints have been shown to enhance skin microcirculation, reduce emotional distress, and facilitate waste elimination by enhancing the autonomic nervous system [43-46]. Improved circulation via a more robust autonomic nerve system is hypothesized to alleviate symptoms associated with chronic kidney disease since the progression of renal failure is linked to inadequate circulation in traditional Chinese medicine. Prominent institutions in the United States, like the Mayo Clinic and Duke University Medical Center, have been offering acupuncture alongside other therapies. As data on the effectiveness and safety of Traditional Chinese Medicine (TCM) increases, medical physicians have become more receptive to its use in clinical practice [47]. It is essential to acknowledge that TCM is not devoid of adverse effects. Huangkui should be administered with care in individuals with hyperlipidemia or liver illness since its usage has been linked to increased lipid levels and hepatic damage. Conversely, acupuncture seems to be comparatively safe, exhibiting little side effects, such as discomfort in the elbow. Additional research on Traditional Chinese Medicine is necessary to evaluate its long-term safety profile, and prescriptions should be made with careful consideration of each patient's health status.

In Ayurveda, silymarin is among the most extensively researched therapies that have shown effectiveness in enhancing renal function. Ayurvedic remedies mostly originate from botanical, zoological, and mineralogical sources, physical activity, and lifestyle modifications. They are said to revitalize and eliminate pollutants from the body. In conventional medicine, the therapeutic benefits of Ayurveda for chronic kidney disease (CKD) are attributed to its anti-inflammatory and antioxidant qualities. Silymarin has shown effectiveness in *in vitro* experiments by reducing inflammatory stress in renal tissue via the inhibition of the NF- κ B signaling pathway and subsequent TNF generation [48-52]. Additional Ayurvedic therapies, including the use of capsaicin ointment, were also discovered to relieve uremic pruritus. Topical capsaicin, a natural alkaloid from red chili pepper, has been shown to alleviate uremic pruritus by directly binding to type C sensory neurons, leading to the release of substance P while subsequently inhibiting its production,

transport, and storage [53]. Minimal side effects were noted for the aforementioned Ayurvedic therapy. Although Ayurvedic therapies provide promising advantages, they are now less recognized worldwide than Traditional Chinese Medicine (TCM) [54]. Additional study is required to assess their effectiveness and safety profile to enhance their adoption in clinical practice as supplementary therapies, particularly for patients with chronic kidney disease (CKD).

Naturopathy's distinctive characteristic is the reordering of therapeutic priorities, placing more focus on non-invasive therapies, such as lifestyle changes and diet, rather than medical or surgical procedures. This study examines the intervention using keto analogues of essential amino acids (KAs). The incorporation of KAs into a low-protein diet has shown improvement in renal function and uremia. Reducing protein consumption may enhance renal function in CKD patients by modifying immunologic processes and decreasing hypertrophy and hyperfiltration in the remaining nephrons; however, it may also lead to malnutrition [55-57]. Nonetheless, the supplementation of KAs not only prevents malnutrition by guaranteeing sufficient intake of amino acids but also mitigates uremia [58]. The lack of amino nitrogen in KAs enables them to undergo transamination by assimilating nitrogen from non-essential amino acids, hence diminishing urea synthesis by the reutilization of the amino group [59,60]. The included naturopathic medicines had very few and minor side effects, making them appealing therapy alternatives. Furthermore, due to their non-invasive nature, naturopathic therapies may be readily integrated with conventional drugs. Notably, 28 health systems, hospitals, and cancer treatment facilities in the United States presently employ at least one licensed naturopathic physician on-site [61]. As research increasingly assesses the effectiveness and safety of naturopathic therapies, its potential function as an additional therapy for CKD patients is expected to grow in the future.

Finally, homeopathy has shown effectiveness in alleviating symptoms and enhancing outcomes associated with chronic kidney disease (CKD). Homeopathy is the therapeutic use of medicines sourced from plants, minerals, or animals that elicit responses mirroring the clinical symptoms of illnesses. This review indicates that Brazilian green propolis tablets enhance renal function, whereas homeopathic verum medicine alleviates uremic pruritus. Brazilian green propolis has been found to enhance renal function in many ways. Initially, it diminishes proteinuria by mitigating urinary oxidative stress and macrophage infiltration in the kidneys [62]. Secondly, chrysin, a flavonoid present in propolis, has shown the ability to reduce podocyte apoptosis in individuals with diabetic nephropathy and mitigate glomerular damage [63]. Finally, propolis has shown the ability to lower blood pressure via acetylcholine-induced vasodilation and its antioxidant characteristics [64-68]. No harmful effects were observed in the investigations concerning the safety of homeopathic medication. Nonetheless, the use of homeopathy is somewhat limited, since 36% of states in the United States mandate that homeopathic practitioners be licensed in either Western medicine or Naturopathic medicine [32]. Therefore, more study is required to confirm the effectiveness and safety of homeopathic treatment as a supplementary therapy for patients with chronic kidney disease (CKD).

Constraints

The following constraints must be taken into account with this evaluation. Initially, the clinical and methodological heterogeneity of the research precluded the execution of meta-analyses. With the expanding database for AMS trials in CKD patients, future reviews have to contemplate using meta-analyses to evaluate the effectiveness of AMS therapies for this population. Moreover, there may have been the exclusion of potentially relevant papers despite the use of a comprehensive search method. To mitigate this, the references of the included papers were manually examined as an element of our search approach. A further restriction of the research pertains to the inclusion of just English-language publications. Researchers need to include findings in other languages, including Chinese and Tamil, in the next evaluations. Ultimately, although the findings of the included trials were presented as normalized Z scores, caution is warranted in interpreting these values and in comparing the effectiveness of different AMS classes. This results from significant variability in the sorts of outcomes assessed, as well as the comparison groups and assessment instruments used. It is anticipated that further standardization of study outcomes

for AMS treatments in forthcoming research would provide more meaningful comparisons of the effectiveness across various AMS classes via these normalized Z scores.

Conclusions

This analysis indicates that TCM and naturopathy were the most extensively researched alternative medical systems, demonstrating benefits in enhancing renal function, reducing proteinuria, and alleviating uremic pruritus in patients with chronic kidney disease (CKD). Most investigations had a limited patient cohort, and bigger randomized controlled trials are needed for further evaluation and validation of these putative AMS remedies. Healthcare practitioners intending to integrate AMS into routine practice should customize therapy according to each patient's health status and be aware of any potential harmful effects.

References

1. Prevalence and disease burden of chronic kidney disease. Lv JC, Zhang LX. *Adv Exp Med Biol*. 2019;1165:3–15.
2. Prevalence and outcomes associated with hypocalcemia and hypercalcemia among pre-dialysis chronic kidney disease patients with mineral and bone disorders. Amanda Yong MH, Benjamin Seng JJ, Cheryl Tan YL, Wong J, How P. *Singapore Med J*. 2022
3. Efficacy and cost-effectiveness of the acupuncture treatment using a new skin stimulus tool called M-test which is a measure based on symptoms accompanied by body movements: a pragmatic RCT targeting hemodialysis patients. Ono S, Mukaino Y. *Evid Based Complement Alternat Med*. 2015;2015
4. Association of anemia and mineral and bone disorder with health-related quality of life in Asian pre-dialysis patients. Wee HL, Seng BJ, Lee JJ, Chong KJ, Tyagi P, Vathsala A, How P. *Health Qual Life Outcomes*. 2016;14:94.
5. The prevalence of symptoms in end-stage renal disease: a systematic review. Murtagh FE, Addington-Hall J, Higginson IJ. *Adv Chronic Kidney Dis*. 2007;14:82–99.
6. CKD-associated pruritus: new insights into diagnosis, pathogenesis, and management. Verduzco HA, Shirazian S. *Kidney Int Rep*. 2020;5:1387–1402.
7. Acupuncture effect on pruritus in hemodialysis patients: a randomized clinical trial. Nahidi Y, Badiie S, Torabi S, Abbasi Z, Nazemian F, Saki A. *Iranian Red Crescent Medical Journal*. 2018
8. Potential factors that influence usage of complementary and alternative medicine worldwide: a systematic review. Tangkiatkumjai M, Boardman H, Walker DM. *BMC Complement Med Ther*. 2020;20
9. Carey WB, Crocker AC, Coleman WL, Elias E, Feldman H. *Developmental-Behavioral Pediatrics* (Fourth Edition) Philadelphia, PA: Elsevier Saunders; 2009. *Developmental-Behavioral Pediatrics* (Fourth Edition)
10. Usage of complementary and alternative medicine among patients with chronic kidney disease on maintenance hemodialysis. Arjuna Rao AS, Phaneendra D, Pavani ChD, Soundararajan P, Rani NV, Thennarasu P, Kannan G. *J Pharm Bioallied Sci*. 2016;8:52–57.
11. Chia BS, Ho SZ, Tan HQ, Chua ML, Tuan JK. A review of the current clinical evidence for loco-regional moderate hyperthermia in the adjunct management of cancers. *Cancers*. 2023 Jan 5;15(2):346.
12. Traditional Chinese medicine in the treatment of symptoms in patients with advanced cancer. Ling Y. *Ann Palliat Med*. 2013;2:141–152.
13. Therapeutic effects of ten commonly used Chinese herbs and their bioactive compounds on cancers. Liu W, Yang B, Yang L, et al. *Evid Based Complement Alternat Med*. 2019;2019
14. Effectiveness of an Ayurveda treatment approach in knee osteoarthritis - a randomized controlled trial. Kessler CS, Dhiman KS, Kumar A, et al. *Osteoarthritis Cartilage*. 2018;26:620–630.
15. Washington, DC: National Academies Press; 2005. *Complementary and Alternative Medicine in the United States*.

16. Effects of homeopathic treatment on pruritus of hemodialysis patients: a randomized placebo-controlled double-blind trial. Cavalcanti AM, Rocha LM, Carillo R Jr, Lima LU, Lugon JR. *Homeopathy*. 2003;92:177–181.
17. Optimized project of traditional Chinese medicine in treating chronic kidney disease stage 3: a multicenter double-blinded randomized controlled trial. Wang YJ, He LQ, Sun W, et al. *J Ethnopharmacol*. 2012;139:757–764.
18. Complementary and alternative medicine therapies for uremic pruritus - a systematic review of randomized controlled trials. Yeam CT, Yo TE, Tan YL, Liew A, Seng JJ. *Complement Ther Med*. 2021;56
19. Chinese herbal medicine for diabetic kidney disease: a systematic review and meta-analysis of randomized placebo-controlled trials. Zhang L, Yang L, Shergis J, et al. *BMJ Open*. 2019;9
20. Astragalus (a traditional Chinese medicine) for treating chronic kidney disease. Zhang HW, Lin ZX, Xu C, Leung C, Chan LS. *Cochrane Database Syst Rev*. 2014
21. Efficacy and safety of the Fu-Zheng-Qu-Zhuo method on retarding the progress of chronic kidney disease (stage 3-4): a systematic review and meta-analysis. Liu SY, Huang P, Zhang N. *Ann Transl Med*. 2019;7.
22. Acupuncture in hemodialysis patients at the Quchi (LI11) acupoint for refractory uraemic pruritus. Che-Yi C, Wen CY, Min-Tsung K, Chiu-Ching H. *Nephrol Dial Transplant*. 2005;20:1912–1915.
23. Efficacy and safety of traditional Chinese medicine (Shenqi particle) for patients with idiopathic membranous nephropathy: a multicenter randomized controlled clinical trial. Chen Y, Deng Y, Ni Z, et al. *Am J Kidney Dis*. 2013;62:1068–1076.
24. Acupuncture treatment for 34 cases of uremic cutaneous pruritus. Gao H, Zhang W, Wang Y. *J Tradit Chin Med*. 2002;22:29–30.
25. Treatment of diabetic nephropathy with *Tripterygium wilfordii* Hook F extract: a prospective, randomized, controlled clinical trial. Ge Y, Xie H, Li S, et al. *J Transl Med*. 2013;11
26. Effect of Ginkgo leaf extract on vascular endothelial function in patients with early-stage diabetic nephropathy. Li XS, Zheng WY, Lou SX, Lu XW, Ye SH. *Chin J Integr Med*. 2009;15:26–29.
27. Efficacy and safety of Tangshan formula on patients with type 2 diabetic kidney disease: a multicenter double-blinded randomized placebo-controlled trial. Li P, Chen Y, Liu J, et al. *PLoS One*. 2015;10
28. Efficacy and safety of *Abelmoschus manihot* for IgA nephropathy: a multicenter randomized clinical trial. Li P, Lin H, Ni Z, et al. *Phytomedicine*. 2020;76
29. Effects of zishentongluo in patients with early-stage diabetic nephropathy. Ma J, Xu L, Dong J, Wei H, Zhi Y, Ma X, Zhang W. *Am J Chin Med*. 2013;41:333–340.
30. Effects of far infrared acupoint stimulation on autonomic activity and quality of life in hemodialysis patients. Su LH, Wu KD, Lee LS, Wang H, Liu CF. *Am J Chin Med*. 2009;37:215–226.
31. Based on HIF-1 α /Wnt/ β -Catenin pathway to explore the effect of Qingshen granules on chronic renal failure patients: a randomized controlled trial. Wang Y, Zhang L, Jin H, Wang D. *Evid Based Complement Alternat Med*. 2019;2019
32. Effects of Qingshen granules on immune function in patients with comorbid chronic renal failure and damp-heat syndrome: a multicenter, randomized, controlled trial. Wang D, Wang Y, Li C, Liu S, Zhang L, Jin H. *Evid Based Complement Alternat Med*. 2020;2020
33. Additive effect of Qidan Dihuang grain, a traditional Chinese medicine, and angiotensin receptor blockers on albuminuria levels in patients with diabetic nephropathy: a randomized, parallel-controlled trial. Xiang L, Jiang P, Zhou L, et al. *Evid Based Complement Alternat Med*. 2016;2016
34. Evaluation of the efficacy and safety of TWHF in diabetic nephropathy patients with overt proteinuria and normal eGFR. Xiong C, Li L, Bo W, Chen H, XiaoWei L, Hongbao L, Peng Z. *J Formos Med Assoc*. 2020;119:685–692.
35. Impact of extended ginsenoside Rb1 on early chronic kidney disease: a randomized, placebo-controlled study. Xu X, Lu Q, Wu J, Li Y, Sun J. *Inflammopharmacology*. 2017;25:33–40.
36. Acupuncture on renal function in patients with chronic kidney disease: a single-blinded, randomized, preliminary controlled study. Yu JS, Ho CH, Wang HY, Chen YH, Hsieh CL. *J Altern Complement Med*. 2017;23:624–631.

37. Efficacy and safety of *Abelmoschus manihot* for primary glomerular disease: a prospective, multicenter randomized controlled clinical trial. Zhang L, Li P, Xing CY, et al. *Am J Kidney Dis.* 2014;64:57–65.
38. Efficacy and safety of Chinese herbal formula granules in treating chronic kidney disease stage 3: a multicenter, randomized, placebo-controlled, double-blind clinical trial. Zhao J, Sun W, Chen J, et al. *Evid Based Complement Alternat Med.* 2020;2020
39. Treatment of chronic kidney disease using traditional Chinese medicine, *Flos Abelmoschus manihot* (Linnaeus) Medicus (Malvaceae) Chen Y, Cai G, Sun X, Chen X. *Clin Exp Pharmacol Physiol.* 2016;43:145–148
40. Triptolide: a potent inhibitor of NF-kappa B in T-lymphocytes. Liu H, Liu ZH, Chen ZH, Yang JW, Li LS. *Acta Pharmacol Sin.* 2000;21:782–786.
41. Triptolide attenuates oxidative stress, NF-κB activation, and multiple cytokine gene expression in murine peritoneal macrophage. Wu Y, Cui J, Bao X, Chan S, Young DO, Shen DL. *Int J Mol Med.* 2006;17:141–150.
42. Triptolide protects podocytes from puromycin aminonucleoside-induced injury in vivo and in vitro. Zheng CX, Chen ZH, Zeng CH, Qin WS, Li LS, Liu ZH. *Kidney Int.* 2008;74:596–612.
43. Triptolide reduces proteinuria in experimental membranous nephropathy and protects against C5b-9-induced podocyte injury in vitro. Chen ZH, Qin WS, Zeng CH, et al. *Kidney Int.* 2010;77:974–988.
44. Brain opiates at work in acupuncture? Pomeranz BH. *New Scientist.* 1977;6:12–13.
45. Far-infrared therapy: a novel treatment to improve access blood flow and unassisted patency of arteriovenous fistula in hemodialysis patients. Lin CC, Chang CF, Lai MY, Chen TW, Lee PC, Yang WC. *J Am Soc Nephrol.* 2007;18:985–992.
46. Biological effect of far-infrared therapy on increasing skin microcirculation in rats. Yu SY, Chiu JH, Yang SD, Hsu YC, Lui WY, Wu CW. *Photodermatol Photoimmunol Photomed.* 2006;22:78–86.
47. The effects of repeated thermal therapy for two patients with chronic fatigue syndrome. Masuda A, Kihara T, Fukudome T, Shinsato T, Minagoe S, Tei C. *J Psychosom Res.* 2005;58:383–387.
48. Sleep-enhancing effects of far-infrared radiation in rats. Honda K, Inoué S. *Int J Biometeorol.* 1988;32:92–94.
49. The study of far infrared therapeutic apparatus on an animal model. Wu BJ. *China Med Devices Infor.* 2001;7:36–38.
50. The clinical experience of wide spectrum far infrared therapy. Hung YH. *Taiwan Neph Nurses Ass.* 2002;1:70–71.
51. Dietary supplementation of silymarin protects against chemically induced nephrotoxicity, inflammation, and renal tumor promotion response. Kaur G, Athar M, Alam MS. *Invest New Drugs.* 2010;28:703–713.
52. Silibinin protects mice from T cell-dependent liver injury. Schümann J, Prockl J, Kiemer AK, Vollmar AM, Bang R, Tiegs G. *J Hepatol.* 2003;39:333–340.
53. Effects of plant-derived polyphenols on TNF-alpha and nitric oxide production induced by advanced glycation endproducts. Chandler D, Woldu A, Rahmadi A, et al. *Mol Nutr Food Res.* 2010;54:141–150.
54. Inhibitory effect of silibinin on tumor necrosis factor-alpha and hydrogen peroxide production by human monocytes. Bannwart CF, Peraçoli JC, Nakaira-Takahagi E, Peraçoli MT. *Nat Prod Res.* 2010;24:1747–1757.
55. Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection. Morishima C, Shuhart MC, Wang CC, et al. *Gastroenterology.* 2010;138:671–81, 681.e1–2.
56. Effect of silymarin administration on TNF-α serum concentration in peritoneal dialysis patients. Nazemian F, Karimi G, Moatamedi M, Charkazi S, Shamsara J, Mohammadpour AH. *Phytother Res.* 2010;24:1654–1657.
57. Silymarin: a novel antioxidant with antiglycation and anti-inflammatory properties in vitro and in vivo. Wu CH, Huang SM, Yen GC. *Antioxid Redox Signal.* 2011;14:353–366.
58. Initiation of dialysis. Hakim RM, Lazarus JM. *J Am Soc Nephrol.* 1995;6:1319–1328
59. Nutritional markers and survival in maintenance dialysis patients. Pollock CA, Ibels LS, Allen BJ. *Nephron.* 1996;74:625–641.

60. Role of dietary factors in the progression of chronic renal disease. Klahr S, Buerkert J, Purkerson ML. *Kidney Int.* 1983;24:579–587.
61. Utilisation of ammonia nitrogen for protein synthesis in man, and the effect of protein restriction and uremia. Richards P, Metcalfe-Gibson A, Ward EE, Wrong O, Houghton BJ. *Lancet.* 1967;2:845–849.
62. Supplements of keto acids in patients with chronic renal failure--more than modulators of nitrogen economy. Druml W. *Wien Klin Wochenschr.* 2001;113:17–18.
63. Naturopathic medicine is growing in U.S. Medical Centers of Excellence
64. Brazilian red propolis attenuates hypertension and renal damage in the 5/6 renal ablation model. Teles F, da Silva TM, da Cruz Júnior FP, et al. *PLoS One.* 2015;10
65. Chrysin ameliorates podocyte injury and slit diaphragm protein loss via inhibition of the PERK-eIF2 α -ATF-CHOP pathway in diabetic mice. Kang MK, Park SH, Kim YH, et al. *Acta Pharmacol Sin.* 2017;38:1129–1140.
66. Anti-hypertensive effects of Brazilian propolis in spontaneously hypertensive rats. Kubota Y, Umegaki K, Kobayashi K, et al. *Clin Exp Pharmacol Physiol.* 2004;31:29–30.
67. Antihypertensive effects of Brazilian propolis: identification of caffeoylquinic acids as constituents involved in the hypotension in spontaneously hypertensive rats. Mishima S, Yoshida C, Akino S, Sakamoto T. *Biol Pharm Bull.* 2005;28:1909–1914.
68. Antihypertensive effects of flavonoids isolated from Brazilian green propolis in spontaneously hypertensive rats. Maruyama H, Sumitou Y, Sakamoto T, Araki Y, Hara H. *Biol Pharm Bull.* 2009;32:1244–1250.

فعالية العلاجات العشبية والبديلة كعلاجات مساعدة لإدارة مرض الكلى المزمن: مراجعة شاملة

الملخص

بشكل كبير على جودة حياة المرضى ويرتبط بالعديد من المضاعفات، بما في ذلك الحكة البولية وفقر (CKD) يؤثر مرض الكلى المزمن: الخلفية (AMS) الدم. غالبًا ما تكون العلاجات التقليدية غير كافية في إدارة هذه الأعراض بشكل فعال، مما يزيد من اهتمام المرضى بأنظمة الطب البديل والأيورفيدا والطب الصيني (TCM) مثل الطب الصيني التقليدي.

تُحلل هذه المراجعة فعالية أنظمة الطب البديل في تخفيف أعراض مرض الكلى المزمن من خلال بحث شامل في قواعد بيانات مثل: الطرق التي تركز (RCTs). تم تضمين التجارب العشوائية المضبوطة 2023، مع تغطية الدراسات المنشورة حتى Scopus وEmbase وMEDLINE الذين يستخدمون العلاجات العشبية والبديلة CKD على مرضى.

تضمنت النتائج CKD. كشفت المراجعة عن فوائد كبيرة لأنظمة الطب البديل، خاصة الطب الصيني التقليدي والأيورفيدا، في إدارة أعراض: النتائج TCM. البارزة انخفاضًا بنسبة 49% في أعراض الحكة مع العلاجات المثلية وتحسن مستويات الهيموغلوبين لدى المرضى الذين تلقوا علاجات تأثيرات على البروتين البولي وتحسين وظائف الكلى على التوالي. Huangkui وsilimarin بالإضافة إلى ذلك، أظهرت العلاجات العشبية مثل وأظهرت دمج أنظمة الطب البديل مع العلاجات التقليدية تأثيرات تآزرية واعدة.

تشير النتائج إلى أن العلاجات العشبية والبديلة يمكن أن تكون علاجات مساعدة فعالة في إدارة مرض الكلى المزمن، خاصة في تخفيف: الاستنتاج الأعراض وتحسين النتائج العامة للمرضى. ومع ذلك، هناك حاجة إلى إجراء تجارب عشوائية مضبوطة واسعة النطاق لتأكيد هذه النتائج ووضع بروتوكولات علاجية موحدة. يجب على مقدمي الرعاية الصحية مراعاة الملفات الشخصية الفردية للمرضى عند دمج أنظمة الطب البديل في خطط العلاج.

مرض الكلى المزمن، الطب البديل، العلاجات العشبية، الطب الصيني التقليدي، نتائج المرضى: الكلمات المفتاحية